🇺🇸 FDA
Pipeline program

Miricorilant 150 mg

CORT118335-861

Phase 1 small_molecule completed

Quick answer

Miricorilant 150 mg for Nonalcoholic Steatohepatitis (NASH) is a Phase 1 program (small_molecule) at CORCEPT THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
CORCEPT THERAPEUTICS INC
Indication
Nonalcoholic Steatohepatitis (NASH)
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials